Eli Lilly Acquisitions — How Pharma’s Biggest Company Spends Its Billions
Every Eli Lilly acquisition, the strategy behind the spending, and what it means for patients and investors.
Eli Lilly is the most acquisitive company in the pharmaceutical industry, committing more than $25 billion across roughly 10 acquisitions in the first half of 2026 alone. That total represents over half of all M&A spending by the world’s top 12 drugmakers in the same period. Lilly’s strategy is straightforward: use record profits from its GLP-1 drugs Mounjaro and Zepbound to build new franchises in cancer, sleep medicine, vaccines, and neuroscience before its obesity dominance peaks.
Key Takeaways
- Eli Lilly committed roughly $25.27 billion across about 10 acquisitions in the first six months of 2026 — more than half of Big Pharma’s combined deal spending.
- Lilly’s GLP-1 drugs Mounjaro and Zepbound generate over 60% of company revenue, creating a concentration risk the acquisitions are designed to solve.
- The largest 2026 deals target sleep medicine (Centessa, up to $7.8 billion) and cancer cell therapy (Kelonia, up to $7 billion).
- Lilly became the first drugmaker to cross a $1 trillion market capitalization, giving it unmatched firepower for deals.
- The company forecasts $82–$85 billion in 2026 revenue, funding continued expansion.
The News That Put Lilly Back in the Spotlight
On July 9, 2026, industry publication Endpoints News reported that Eli Lilly completed 11 biotech transactions in the first half of 2026, dominating the industry’s M&A total. The report landed the same week Lilly announced 16 research presentations for the Alzheimer’s Association International Conference in London (July 12–15) and days after JPMorgan raised its price target on the stock ahead of August earnings.
Three separate headlines, one underlying story: the world’s most valuable drugmaker is deploying capital at a pace the pharmaceutical industry has never seen. To understand why, you have to look at where Lilly’s money actually comes from.
The Engine: Two Drugs, One Trillion Dollars
Eli Lilly’s transformation began with tirzepatide, the molecule sold as Mounjaro for type 2 diabetes and Zepbound for obesity. Mounjaro leads new prescriptions among diabetes incretin drugs in both U.S. and international markets. Zepbound holds close to 70% of new prescriptions in the branded obesity market.
Together, these GLP-1 therapies account for more than 60% of Eli Lilly’s total revenue. The financial results have been historic:
| Metric | Figure | Context |
|---|---|---|
| Market capitalization | ~$1.06 trillion | First pharma company ever above $1T |
| Stock price (July 2026) | ~$1,214 | Up 56.9% in one year, from ~$774 |
| 2025 revenue | $65+ billion | Up 45% year-over-year |
| 2026 revenue guidance | $82–$85 billion | Raised after Q1 earnings beat |
| 2026 EPS guidance | $35.50–$37.00 | Non-GAAP |
| Q1 2026 earnings surprise | +25.92% | Fourth consecutive beat |
In June 2026, the FDA-approved oral pill Foundayo (orforglipron) added a third pillar — the only approved GLP-1 pill that can be taken any time of day without food and water restrictions. And beginning July 1, 2026, Lilly’s Medicare GLP-1 Bridge program opened the first broad Medicare Part D pathway for obesity medicines, offering eligible patients Foundayo or Zepbound at $50 per month through December 2027.
So why would a company this dominant go on the largest buying spree in pharmaceutical history? The answer lies in a pattern every drugmaker eventually faces.
The Patent-Cliff Logic Behind the Spending
Pharmaceutical revenue is built on temporary monopolies. When patents expire, generic and biosimilar competition typically erases the majority of a drug’s sales within a few years. A company earning 60% of its revenue from one molecule family is, by industry logic, a company on a timer.
Lilly’s management understands this pattern intimately. The company’s own history includes the “Year of Yikes” era after Prozac lost exclusivity in 2001, when revenue stalled for years. The lesson institutionalized inside Lilly: reinvest peak-cycle profits into the next generation of medicines before the current cycle ends.
That is the mechanism driving 2026’s deal frenzy. Lilly is not shopping from weakness or desperation — it is shopping from a rare position where cash flow, stock currency, and time are all simultaneously in its favor.
Inside the 2026 Acquisition Spree
Lilly’s 2026 purchases follow a clear diversification map — each deal plants a flag in a therapy area outside metabolic medicine:
| Target | Deal Value | Therapy Area | Announced |
|---|---|---|---|
| Orna Therapeutics | ~$2.4 billion | Cell therapy (in-body CAR-T) | February 2026 |
| Centessa Pharmaceuticals | $6.3B (up to $7.8B) | Sleep disorders (orexin agonists) | March 2026 |
| Kelonia Therapeutics | Up to $7 billion | Cancer cell therapy | April 2026 |
| Ajax Therapeutics | ~$2.3 billion | Blood cancers (MPN) | April 2026 |
| Curevo Inc. | Undisclosed | Vaccines | 2026 |
| LimmaTech Biologics | Undisclosed | Vaccines | 2026 |
| 4E Therapeutics | Undisclosed | Neuropathic pain | June 2026 |
Beyond outright acquisitions, Lilly signed 11 major licensing deals in the same window — including a partnership worth up to $2.25 billion with AI-driven Profluent Bio for DNA editing tools, an expanded collaboration with China’s Abbisko Therapeutics worth up to $1.9 billion, and a GLP-2 program with South Korea’s Hanmi for short bowel disease.
For a decade-long perspective: Lilly has completed around 30 buyouts in ten years — more than any other top-12 pharma — totaling roughly $54 billion. Nearly half of that decade’s spending happened in the first six months of 2026 alone.
How Lilly Compares to Its Rivals
Lilly’s spending dwarfs the competition in volume, though not always in single-deal size:
| Company | H1 2026 M&A Commitment | Largest Deal |
|---|---|---|
| Eli Lilly | ~$25.27 billion (10 deals) | Centessa, up to $7.8B |
| Gilead Sciences | ~$14.8 billion | — |
| GSK | ~$13.5 billion | Nuvalent, $10.6B |
| AbbVie | — | Apogee Therapeutics, $10.9B |
| Sun Pharma | — | Organon, ~$12.6B |
The contrast reveals Lilly’s distinct philosophy: rather than one transformative mega-merger, it prefers many mid-sized bets across different scientific approaches. This mirrors the strategy that produced its current success — the 2019 Loxo Oncology acquisition, long Lilly’s biggest deal, seeded the cancer pipeline the company is now doubling down on.
The strategy has a second, less obvious advantage — and it explains why competitors can’t simply copy it.
The Advantage Money Can’t Buy Alone
With $7.3 billion in cash, $65+ billion in annual revenue, and a stock trading above $1,000 per share, Lilly can outbid nearly anyone. But its real edge is speed of conviction. Industry trackers counted 52 biopharma M&A deals across the whole sector in the first half of 2026 — a resurgence that has biotech boards running competitive auction processes. In that environment, the buyer who decides fastest wins, and Lilly has closed deals at a pace of more than one per month.
Meanwhile, the company keeps feeding its scientific engine. At the July 2026 Alzheimer’s conference, Lilly is presenting long-term data on its Alzheimer’s therapy Kisunla (donanemab) and new results showing P-tau217 blood tests can identify Alzheimer’s pathology in people without symptoms — a potential replacement for expensive brain scans. If blood-based diagnosis scales, the market for Alzheimer’s treatment expands dramatically, and Lilly is positioned on both the diagnostic and therapeutic sides.
What This Means for You
For ordinary readers, Lilly’s strategy touches daily life in two ways: Medicare patients gained their first broad coverage path to obesity drugs at $50 a month, and the pipeline being assembled today — in sleep, cancer, pain, and Alzheimer’s — shapes which diseases get new treatments in the 2030s. For investors, the question is concentration: a $1 trillion valuation still rests heavily on two GLP-1 molecules, and the acquisitions are a multi-year bet that has not yet produced its first blockbuster.
Frequently Asked Questions
How many companies has Eli Lilly acquired in 2026? Eli Lilly signed roughly 10 acquisition deals in the first half of 2026, worth about $25.27 billion combined. It also signed 11 major licensing partnerships in the same period, bringing total transactions to over 20.
What is Eli Lilly’s biggest acquisition of 2026? The Centessa Pharmaceuticals deal is Lilly’s largest of 2026, valued at $6.3 billion upfront and up to $7.8 billion with milestones. Centessa develops orexin receptor agonists for sleep disorders such as narcolepsy.
Why is Eli Lilly buying so many companies? Lilly earns more than 60% of its revenue from the GLP-1 drugs Mounjaro and Zepbound. The acquisitions diversify the company into cancer, sleep medicine, vaccines, and pain treatment before GLP-1 competition and eventual patent expirations erode that revenue base.
Is Eli Lilly the biggest pharmaceutical company in the world? Yes. Eli Lilly is the world’s most valuable drugmaker, with a market capitalization of roughly $1.06 trillion as of July 2026 — the first pharmaceutical company ever to cross the $1 trillion mark.
What drugs make Eli Lilly the most money? Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity) are Lilly’s top sellers, together generating over 60% of company revenue. The oral GLP-1 pill Foundayo (orforglipron) launched in 2026 as a third growth driver.
What is Eli Lilly’s revenue forecast for 2026? Eli Lilly projects $82 billion to $85 billion in 2026 revenue, with non-GAAP earnings per share of $35.50 to $37.00 — guidance the company raised after beating Q1 estimates by nearly 26%.
Official Sources
- Eli Lilly and Company — Investor Relations & Press Releases: https://investor.lilly.com
- U.S. Securities and Exchange Commission — Lilly filings: https://www.sec.gov
- U.S. Food & Drug Administration — Drug approvals database: https://www.fda.gov
Editorial Note
TruePickUS covered this story because most reporting counts Lilly’s deals without explaining the revenue-concentration mechanism that drives them. This article will be updated after Lilly’s Q2 2026 earnings report in August and whenever a new acquisition above $1 billion is announced.
About the author: William Harris is a U.S. business and finance correspondent at TruePickUS covering pharmaceutical and healthcare markets. This analysis is based on verified public filings, company press releases, and official disclosures.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock prices, valuations, and deal terms reflect data available as of July 10, 2026, and may change. Consult a licensed financial advisor before making investment decisions.
